SLC5A2 and diabetes mellitus: According to the evidence from large trials assessing the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular or renal outcomes, the cardiorenal benefits of SGLT2 inhibitors have already been extended from patients with type 2 diabetes mellitus (T2DM) (1–5) to patients with heart failure (HF) (6, 7) and those with chronic kidney disease (CKD) (8).